Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Oct;20(5):284-9.
doi: 10.1258/vasc.2011.201206. Epub 2012 Oct 19.

Stem cell therapy for critical limb ischemia: what can we learn from cell therapy for chronic wounds?

Caroline Jadlowiec  1 , Robert A Brenes, Xin Li, Wei Lv, Clinton D Protack, Michael J Collins, Alan Dardik
Affiliations
Review

Stem cell therapy for critical limb ischemia: what can we learn from cell therapy for chronic wounds?

Caroline Jadlowiec et al. Vascular. 2012 Oct.

Abstract

Although much progress has been made regarding our knowledge of stem cells and their potential applications for therapeutic angiogenesis, there has been less success with the clinical application of this knowledge to patients with critical limb ischemia (CLI). Patients with CLI often have chronic wounds and newer cell-based therapies for chronic wounds show interesting parallels to stem cell therapy for CLI. Several human-derived wound care products and therapies, including human neonatal fibroblast-derived dermis (Dermagraft®), bilayered bioengineered skin substitute (Apligraf®), recombinant human platelet-derived growth factor and autologous platelet-rich plasma may provide insight into the mechanisms through which differentiated cells can be used as therapy for chronic wounds, and, analogously, by which stem cells might function therapeutically in CLI.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Sequential photographs of a wound unresponsive to conventional dressings treated with human neonatal fibroblast-derived dermis (Dermagraft®); A) At time of presentation, B) 2 weeks, C) 4 weeks, D) 6 weeks, E) 8 weeks
See this image and copyright information in PMC

References

    1. Asahar T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of Putative Progenitor Endothelial Cells for Angiogenesis. Science. 1997;275:964–967. - PubMed
    1. Curran MP, Plosker GL. Bilayer Bioengineered Skin Substitute (Apgraf) Biodrugs. 2002;16(6):439–455. - PubMed
    1. Diehm C, Trampisch H, Haberl R, Darius H, Mahn M, Pittrow D, et al. Prognosis of patients with asymptomatic versus symptomatic peripheral arterial disease: 3-year results of the get ABI study. Vasc Med. 2007;12:141–148.
    1. Eppley BL, Woodell JE, Higgins J. Platelet Quantification and Growth Factor Analysis from Platelet-Rich Plasma: Implications for Wound Healing. Plast Reconstr Surg. 2004;114(6):1502–8. - PubMed
    1. Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis. 2010;209:10–17. - PubMed

Publication types